Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma ” or the “Company ”), "Company"), a ...
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer One hundred sixty-two patients ...
Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7 ...
BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart ...
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial One ...
Morning Overview on MSN
Eli Lilly says retatrutide met goals in its first phase 3 diabetes trial
Eli Lilly disclosed that retatrutide, its experimental triple hormone receptor agonist, hit the primary and all key secondary ...
ChemR23 agonism targets inflammatory and neurosensory biology, with receptor expression on ocular immune cells and dorsal root ganglion neurons/glia supporting a mechanistic rationale for NCP symptom ...
While a randomized controlled trial of vitamin D 3 supplementation in COVID-19 patients didn’t yield a significant reduction ...
Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results